PDCD1 and Pruritus: Compared with neoplastic subjects getting chemotherapy, PD-1/PD-L1 inhibitor-treated subjects presented a greater risk of developing pruritus, and rash; however, anti-PD1/PD-L1 treatment presented a lesser risk of provoking pruritus with respect to ipilimumab.